Leadership
Team

The Clinigen US team has the expertise, dedication, and drive to successfully navigate the complexities and challenges that can impact patients, healthcare professionals, pharmaceutical and biotechnology companies, and clinical researchers.










If your actions inspire others to dream more, learn more, do more, and become more, then you are a leader.

President John Quincy Adams








James Meyer
General Manager, US Commercial Medicines

James joined the Clinigen group in May 2019 as general manager, US Commercial Medicines. In this role, James has been tasked with building and leading Clinigen’s first commercial business operation in the United States.

James is an accomplished executive who has over 36 years of experience in the pharmaceutical industry, bringing a wealth of knowledge and a deep understanding of US-based oncology sales and marketing. He is particularly suited to build and lead the commercial infrastructure for Clinigen, Inc, to support its commercial medicines business in the United States.

Before Clinigen, James was president of JPM Pharma Commercial Development, LLC, a consulting company specializing in the commercial development of oncology-based biopharmaceutical products. Previously, James led Teva Pharmaceutical’s oncology new products division in the United States for 5 years and was responsible for the commercial development and launch of multiple oncology products. Additionally, he played a key role in the development of commercial strategy and business development for the US oncology business unit.

Before Teva, James was senior vice president of commercial operations at TenX BioPharma, Inc, and was responsible for overseeing the worldwide commercial development of zanolimumab, an anti-CD4 antibody for T-cell lymphomas. James also worked at Wyeth (now Pfizer) for 28 years in a variety of national sales management, marketing, commercial development, and operational roles across multiple therapeutic areas. Prior to the Pfizer acquisition, he led Wyeth’s global oncology new business division and was responsible for the commercialization of Wyeth’s global oncology pipeline, as well as the search for potential in-licensing of oncology assets.

 

Julie Gosper
Vice President, Products Business Development

TBD

 

James Dewis
Director, Cell Therapy Business & Alliance Management

James has worked in the Clinigen business for 15 years, moving from the United Kingdom to the United States in 2008 to establish the local clinical trials business. After a decade in clinical trials services, James worked in the unlicensed medicine business, and in corporate development, where he worked on market development and the acquisition and integration of CSM and Proleukin® (aldesleukin).

Today James works in the commercial medicines business, overseeing Clinigen activities in cell therapy. This is central to Clinigen’s ongoing partnerships to explore use of interleukin-2 (IL-2) with pharmaceutical companies, academic investigators, and researchers to ensure they can access the only IL-2 approved by the US Food and Drug Administration (FDA) for use as a human medicine. Clinigen also partners with scientific and medical communities that are investigating Proleukin across a wide variety of indications, regimens, and therapeutic approaches.

 

Henno Welgemoed, MD
Director of Medical Affairs, Clinigen Group

Dr. Welgemoed is a qualified physician with 17 years of clinical expertise and over 20 years of pharmaceutical experience. Dr. Welgemoed’s clinical background is general medicine with a special interest in hematology-oncology, infectious disease immunology, and rare disease.

Throughout his career, Dr. Welgemoed has fulfilled various roles across commercial, new business development, and medical affairs globally. For the past 5 years, Dr. Welgemoed has been based in the United Kingdom, serving as the global director of Medical Affairs for the Clinigen Group.